Shares of Torrent Pharmaceuticals Ltd climbed nearly 2% to ₹3,695.40 on the NSE on Tuesday, after the company posted a 20% year-on-year increase in consolidated net profit to ₹548 crore for the June quarter of FY26. This compares to ₹457 crore in the same period last year.
The robust performance was driven by strong revenue growth across key markets, including India and the US. Revenue from operations rose 11% YoY to ₹3,178 crore from ₹2,859 crore.
In India, which is Torrent’s largest market, revenues grew 11% YoY to ₹1,811 crore, with the company citing outperformance in focus therapies.
US business revenue jumped 19% YoY to ₹308 crore, while Brazil sales climbed 11% to ₹218 crore. Meanwhile, Germany sales also saw a 9% increase, contributing ₹308 crore.
The strong Q1 print reflects Torrent’s continued momentum in international markets and a stable performance in India. Analysts say the consistent growth in both developed and emerging markets highlights Torrent’s execution strength and diversified geographic mix.
